Drug or treatment

Quizartinib clinical trials

• 7Clinical trials
• 7Countries

Newest trials

All recruiting trials (7)

• Venetoclax and Azacitidine with or without Quizartinib in older/unfit adults with AML

  This trial tests whether adding Quizartinib to Venetoclax and Azacitidine helps older or unfit adults with AML live longer compared with the standard Venetoclax and Azacitidine therapy.

  Recruiting at 24 sites Phase 3 PETHEMA Foundation · Santiago de Compostela, A Coruña and 51 other locations · NCT07478991

• Quizartinib maintenance at two doses for FLT3‑ITD positive AML in first complete remission

  This trial tests whether two different doses of quizartinib can help prevent relapse in adults with FLT3‑ITD positive AML who are in first complete remission and have not had an allogeneic stem cell transplant.

  Recruiting at 50 sites Phase 2 Daiichi Sankyo · Birmingham, Alabama and 63 other locations · NCT06824168

• Ziftomenib plus quizartinib dose-finding for relapsed/refractory AML with NPM1, KMT2A, or NUP98 alterations

  This trial tests an all-oral combination of ziftomenib and quizartinib in adults with relapsed or refractory AML that has NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT06769490

• Evaluating quizartinib in patients with severe liver impairment

  This study is testing how a single dose of quizartinib affects people with severe liver problems compared to healthy individuals to see if it's safe and how the body processes the medication.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Miami, Florida and 2 other locations · NCT06740799

• Combining Quizartinib with Chemotherapy for Pediatric AML Patients

  This study is testing if adding a new drug called quizartinib to standard chemotherapy can help children with a specific type of leukemia feel better and have better treatment outcomes.

  Recruiting Phase 2 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06262438

• Investigating Ziftomenib with Other Treatments for Acute Myeloid Leukemia

  This study is testing if a new drug called ziftomenib, when combined with other treatments, can help people with acute myeloid leukemia who have certain genetic mutations feel better and stay safe during treatment.

  Recruiting at 44 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 43 other locations · NCT05735184

• Combining cladribine, idarubicin, cytarabine, and quizartinib for treating acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of four drugs to see if it can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04047641

Quick answers

How many clinical trials of Quizartinib are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (5 trials), Australia (1 trial), Brazil (1 trial), China (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 2: 2, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →